RxDoctor Payments Data

Aileen Anglin

Acute Care · Houston, TXNPI 1083886014

Payments from drug & device makers

$3,298in general payments, 2019–2025

Across 21 payments — averaging $157.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$1K
  • Pharmacosmos Therapeutics Inc.$640
  • Johnson & Johnson$315
  • Regeneron Healthcare Solutions, Inc.$248
  • AstraZeneca$246
  • Astellas Pharma US Inc$217
  • plus $577 from 6 others

What the payments were for

  • Consulting fees$1,05532%
  • Speaking & faculty fees$60018%
  • Food & beverage$1,36141%
  • Education$2829%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,298 in reported general payments places this provider in the 90th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$28,018
Medicare patients
110
Services billed
372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate63$1,039,638
TabrectaCapmatinib Hydrochloride16$323,621
RevlimidLenalidomide15$271,984
GilotrifAfatinib Dimaleate14$152,079
EliquisApixaban35$35,868
XareltoRivaroxaban18$15,495
Dexamethasone62$782
Ondansetron Hcl87$759
Levothyroxine Sodium79$593
Gabapentin37$494
Prochlorperazine Maleate49$448
Anastrozole23$394
Triamcinolone Acetonide24$345
Potassium Chloride27$254
Mirtazapine24$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTagrisso$246$1,039,63863 claims
PfizerEliquis$82$35,86835 claims
Johnson & JohnsonXarelto$315$15,49518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,323 acute care providers in Texas.

Other acute care in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →